Note: Although the same hybrid genes issued from ABL and BCR are the hallmark of the t(9;22) translocation, this translocation may be seen in the following diseases: CML, ANLL, and ALL, and will therefore be described in the 3 different situations: t(9;22)(q34;q11) in CML, t(9;22)(q34;q11) in ALL, t(9;22)(q34;q11) in ANLL. t(9;22)(q34;q11) in ALL is herein described. 
Clinics and Pathology
Disease ALL Phenotype / cell stem origin L1 or L2 ALL; most often with B-cell phenotype, rare T-cell cases; heterogeneity of lineage involvement: may either be a multipotent stem cell, or a lymphoidcommitted progenitor. Epidemiology 20% of adult ALL, 2-5% of children ALL. Clinics Frequent CNS involvement, even at diagnosis; blood data: high WBC (50-150 X 10 9 /l).
Cytology
CD10+ in most cases, sometimes CD19+ CD10-. Treatment BMT is indicated. Prognosis Is very poor, especially in lymphoid-committed progenitor cases; the breakpoint in M-bcr or in m-bcr (see below) does not seem to have impact on prognosis.
Cytogenetics

Cytogenetics, morphological
The chromosomal anomaly disappears during remission, in contrast with BC-CML cases when treated with conventional therapies.
Cytogenetics, molecular
Is useful to uncover a 'masked Philadelphia' chromosome, where chromosomes 9 and 22 all appear to be normal, but where cryptic insertion of 3' ABL within a chromosome 22 can be demonstrated.
Additional anomalies
Found in 50 to 80% of cases: +der (22), -7, del(7q) most often, +8, but not an i(17q), in contrast with CML and ANLL cases; complex karyotypes, often hyperploid, are frequent.
Variants t(9;22;V) and apparent t(V;22) or t(9;V), where V is a variable chromosome, may be found, as in CML. 
Genes involved and Proteins
Results of the chromosomal anomaly
Hybrid gene
Description
The crucial event lies on der(22), id est 5' BCR/3' ABL hybrid gene is pathogenic, while ABL/BCR may or may not be expressed; -breakpoint in ABL is variable over a region of 200 kb, often between the two alternative exons 1b and 1a, sometimes 5' of 1b, or 3' of 1a, but always 5' of exon 2; -breakpoint in BCR is either: 1-in the same region as in CML, called M-bcr (for major breakpoint cluster region), a cluster of 5.8 kb, between exons 12 and 16, also called b1 to b5 of Mbcr; most breakpoints being either between b2 and b3, or between b3 and b4; transcript is 8.5 kb long; this results in a 210 kDa chimeric protein (P210), with the first 902 or 927 amino acids from BCR; 2-in a 35 kb region between exons 1 and 2, called mbcr (minor breakpoint cluster region), → 7 kb mRNA, resulting in a 190 kDa protein (P190), with the 427 Nterminal amino acids from BCR. Transcript 7 or 8.5 kb.
Fusion protein
Description 190 or 210 kDa (see diagram); BCR/ABL has a cytoplasmic localization, in contrast with ABL, mostly nuclear; this may have a carcinogenetic role. The hybrid protein has an increased protein kinase activity compared to ABL: 3BP1 (binding protein) binds normal ABL on SH3 domain, which prevents SH1 activation; with BCR/ABL, the first (N-terminal) exon of BCR binds to SH2, hidding SH3 which, as a consequence, cannot be bound to 3BP1; thereof, SH1 is activated. Oncogenesis 1-Proliferation is induced: there is activation by BCR/ABL of Ras signal transduction pathway via it's linkage to son-of-sevenless (SOS), a Ras activator; PI3-K (phosphatidyl inositol 3' kinase) pathway is also activated; MYC as well; 2-BCR/ABL inhibits apoptosis; 3-BCR/ABL provokes cell adhesive abnormalities: impaired adherence to bone marrow stroma cells, which allows unregulated proliferation of leukaemic progenitors.
To be noted
Blast crisis is sometimes at the first onset of CML, and those cases may be undistinguishable from true ALL with t(9;22) and P210 BCR/ABL hybrid.
